Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2021) 75 P10 | DOI: 10.1530/endoabs.75.P10

1Fondazione Policlinico Universitario A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome Italy; [email protected]; 2Fondazione Policlinico Universitario A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome Italy

Background: Ghrelin and its endogenous antagonist liver-expressed antimicrobial peptide-2 (LEAP-2) are involved in GH secretion, both acting on GSH-r1α, and regulation of glucose and lipids metabolism. Metabolic impairments are often accompanied by an upregulation of LEAP-2 expression, with a usual concomitant reduction in ghrelin secretion. Adult growth hormone deficiency (aGHD), characterized by weight gain, increased fat mass and insulin resistance, represent a condition of metabolic derangement.

Objectives: The primary objective of this cross-sectional observational pilot study was to compare circulating LEAP-2 and ghrelin serum levels in aGHD and healthy controls.

Methods: 30 patients were included in the study. Group A included adult GHD: 15 patients, 8 females and 7 males. Median and interquartile range age of the group was 53 (41–57) years, while BMI was 27.1 (25–35) kg/m2. Group B was formed by 15 healthy controls (10 females and 5 males). Median and interquartile range age was 47 (36–57) years, while BMI 22.9 (20.8-33.1) kg/m2. They were evaluated for serum glucose and insulin, HOMA-index, QUICKI-index, total/lDL/HDL cholesterol, triglycerides, IGF-1, ghrelin and LEAP-2.

Results: Ghrelin levels in the aGHD group were significantly lower than in healthy controls. In contrast, LEAP-2 showed a trend toward higher levels, although the differences were not significant. However, LEAP-2/Ghrelin molar ratio, an index of receptor affinity, was significantly higher in aGHD. No significant correlations between ghrelin and LEAP-2 with BMI, HOMA index and other parameters were found in aGHD population. However, a significant inverse correlation (r2=0.15, P=0.047) between BMI and ghrelin was evidenced when considering the whole population.

Conclusions: These results may suggest a body adaptation to a metabolic scenario typical of aGHD. The decrease in ghrelin production could prevent further weight gain and fat mass increase, although losing its secretagogue effect.

Volume 75

ESE Young Endocrinologists and Scientists (EYES) Annual Meeting

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.